Abstract

Glioblastoma is the most common primary malignancy of the central nervous system. Maximal surgical resection of glioblastoma in addition to temozolomide and fractionated radiation therapy provides an overall median survival of approximately 15 months. The addition of tumor-treating fields (Optune therapy) has the potential to increase median survival to 20 months, although compliance and ease of use remain an issue. Glioblastoma remains a devastating diagnosis fraught with complications. Curcumin is a yellow pigment from the rhizome of the ubiquitous and commercially available spice, turmeric (Curcuma longa). Turmeric has been long used in Indian traditional medicines and has been established as a safe food additive by the US Food and Drug Administration. There is a wealth of in vitro data suggesting that turmeric’s main active component, curcumin, has many favorable effects on glioblastoma. Curcumin has been shown to potentiate the effects of chemotherapy and radiation, decrease malignant spread, protect normal tissue from oxidative stress, and regulate many genetic targets resulting in glioblastoma cell death. Curcumin’s positive safety profile and potential therapeutic effects on glioblastoma make it a promising potential adjunct to current standard treatment regimens.

INTRODUCTION

Gliomas have historically been divided into 4 grades by WHO classification, with highly variable prognosis between the histologic grades. WHO grade I gliomas include pilocytic astrocytoma, subependymoma, subependymal giant cell astrocytoma, ganglioglioma, desmoplastic infantile astrocytoma, and myxopapillary ependymoma, among others. WHO grade II gliomas are infiltrative and generally more aggressive than grade I tumors and include oligodendroglioma, fibrillary astrocytoma, pleomorphic xanthoastrocytoma, and mixed oligoastrocytoma, as well as other less common tumor types. WHO grade III gliomas include anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic ganglioglioma, anaplastic ependymoma, and anaplastic pleomorphic xanthoastrocytoma. Finally, WHO grade IV gliomas include glioblastoma, various subtypes of glioblastoma, and pinealoblastoma (1). Within the category of diffuse, infiltrating gliomas (WHO II, III, IV), tissue diagnosis was traditionally made based on histopathologic analysis based on the presence or absence of microvascular proliferation, necrosis, and mitotic activity. The introduction of genetic profiling of gliomas based on IDH mutation, MGMT promoter methylation status, 1p/19q codeletion has led to better understanding and more appropriate classification of gliomas and their subtypes (1).

With an annual incidence of 3.21 per 100,000 individuals, glioblastomas are the most common primary malignant brain tumor with nearly 11,000 new cases diagnosed each year in the United States (2). According to the CBTRUS data repository, glioblastoma accounted for 14.5% of all CNS tumors, 57.7% of all gliomas, and 48.6% of all malignant CNS tumors diagnosed from 2013–2017 (2). Prognosis for patients with glioblastoma remains dismal. Aggressive maximal resection followed by radiotherapy has a median overall survival of 12.1 months. The addition of adjuvant alkylating chemotherapy with temozolomide (TMZ) and radiotherapy after surgery (Stupp protocol) increased median overall survival time to 14.6 months (3). Optune^® therapy (Novocure Inc., Haifa, Israel) is a wearable technology that delivers low intensity alternating electrical fields over the scalp. Tumor-treating fields along with maximal surgical resection and Stupp regimen increases median overall survival time to 20.9 months, although it has not been used clinically in a widespread manner (4). It is important to note that median overall survival for all cases of glioblastoma is around 8 months (2).

Given the poor prognosis for patients with newly diagnosed glioblastoma, it is imperative that efforts for drug development continue in order to improve upon current standard-of-care therapies. Curcumin, a yellow pigment, derives from the rhizome of the ubiquitous and commercially available spice, turmeric (Curcuma longa). Turmeric has been long used in traditional Indian Ayurvedic medicine, with its medicinal use dating back to 2500 years ago, and more recently for its anti-inflammatory properties (5). Curcumin has also been studied for its apparent anti-tumor effects systemically. More recently, Curcumin has become an interesting consideration for glioblastoma treatment because of its modulation of multiple targets which appear to suppress tumors, decrease malignant characteristics, promote apoptosis, and potentiate the effects of chemotherapy and radiation (6–9). Interestingly, the number of peer-reviewed publications related to curcumin has been steadily increasing over the past 20 years, with an expanding portfolio of scientific reports pertaining to curcumin and gliomas.

CHEMICAL AND PHYSICAL PROPERTIES OF CURCUMIN

Curcumin ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is one of three phytoconstituents (non-nutrient bioactive compound) of turmeric; the other two phytoconstituents are bis(demethoxy)curcumin and demethoxycurcumin (Figure 1). Together, these compounds account for under 10% of turmeric’s dry weight (10, 11). After removing the protein, carbohydrates, fats, minerals, volatile oils, and fiber from raw turmeric, a crude curcuminoid extract is generated, consisting of 60–70% curcumin, 20–27% demethoxycurcumin, and 10–15% bis(demethoxy)curcumin.

Figure 1

Curcuminoids extracted from the rhizome of turmeric (Curcuma longa) and molecular structures of the three phytoconstituents: curcumin, demethoxycurcumin, and bisdemethoxycurcumin.

The molecular weight of curcumin is 368.38 daltons. Curcumin’s β-ketone moiety exhibits keto-enol tautomerization, with the enol form predominating in alkaline solution. It is essentially insoluble in water at room temperature and has a neutral pH. Curcumin is photoactive and absorbs light wavelengths in the visible range of 408–500 nm and exhibits photodegradation. At 37 °C the half-life at pH 7.2 is less than 10 minutes; in vitro degradation of curcumin occurs via nucleophilic substitution or elimination by solvent molecules (solvolysis), and oxidative degradation (10).

In vivo studies indicate that the bioavailability of unaltered curcumin preparations (standard curcumin) is very poor; 12 g oral doses of curcumin administered to healthy human subjects produced serum concentrations of 50.5 ng/ml, although other studies saw increased concentrations with concomitant administration of piperine–the alkaloid responsible for the pungency of black pepper (Piper nigrum)–indicating that bioavailability concerns can be at least partially addressed (12, 13). For orally ingested doses, the bioavailability issue seems to start with intestinal mucosa via modification by glucuronidation and sulfonation. Orally administered curcumin doses of 3.6 g are detected in colorectal tissue; however, in other studies utilizing this dose range, the serum concentration was nearly undetectable (12, 14). During phase I metabolism, oxidoreductases contribute to the reductive metabolism of curcumin. In phase II metabolism, intestinal epithelial cells’ glucuronosyltransferases and sulfotransferases act by glucuronidation and sulfonation of curcumin. The majority of curcumin that reaches systemic circulation is reduced, conjugated, and excreted in feces, not exhibiting pharmacodynamic effects outside of the alimentary system (15).

TOXICITY

Curcumin is a very well tolerated substance. Daily intake of curcumin can approach 3 mg/kg/day; side effects in people ingesting 500–12,000 mg doses included headache, rash, and yellow stool (16). Multiple studies regarding the safety of orally ingested curcumin have been conducted. A phase 1 trial with 25 participants ingesting 8,000 mg curcumin per day for three months demonstrated no toxicity; five other studies using smaller doses (1,125–2,500 mg) also demonstrated curcumin’s safety (17). If toxicity does occur, it is likely via curcumin’s extensive interaction of hERG (human Ether-à-go-go-related gene) channels, cytochrome P450, or drug-drug interactions. In rat models, inhibition of cytochrome P450 has caused cardiotoxicity, while interaction with glutathione S-transferase has caused drug-drug interactions (10). Curcumin has been shown to induce cytotoxicity in human lymphocytes and renal cell lines at IC50 concentrations of 15.2 μM and 31 μM, respectively (10). Currently, the FDA has not approved curcumin as a treatment for any condition and it remains classified as a safe food additive at levels from 0.5 to 100 mg per 100 g of food.

CURCUMIN AND SIGNAL CASCADE PROTEINS

Curcumin appears to modulate many cellular processes, allowing it to act as an in vitro tumor suppressor, decrease malignant characteristics, promote apoptosis, and potentiate the effects of chemotherapy and radiation. Curcumin has been shown to interact with Wnt, HDGF, STAT3, and NRF2, which will be discussed in detail below.

CURCUMIN DECREASES TUMOR INVASIVENESS

The malignant nature of gliomas is often due to the fact that tumor cells infiltrate deep into the parenchyma, distal to observable tumor margins; this makes complete surgical resection impossible (37). Biopsy studies in glioblastoma patients have shown that tumor cells can be found well beyond the MRI T2 hyperintense margins (38). Glioma invasion is promoted by the expression of matrix metalloproteinases (MMPs). MMPs are zinc-dependent proteolytic endopeptidases that degrade extracellular matrix proteins and cell adhesion molecules, allowing tumor cells to become locally invasive (39). Through a complex interaction with vascular endothelial growth factor (VEGF) and its receptor, VEGFR2, MMP-2 has been implicated in vasculogenesis, angiogenesis and disseminated tumor growth (39, 40). MMP-9 may promote vasculogenesis in the absence of VEGF (40). Large diameter gliomas appear to have greater expression of MMP-2 than their smaller counterparts, with an accompanying decrease in expression of their inhibitor proteins (40). In one study, U373 glioblastoma cells treated with curcumin solution had measurable decreases in multiple MMPs including MMP-2 (41). Another study specifically examining invasion distance of SNB19 and A1027 glioblastoma cells after treatment with 10 μM, 15 μM and 20 μM curcumin solutions found that treated cell lines had significantly less migration (invasion) than controls (8). Increased expression of MMPs may very well contribute to the invasive properties of high-grade gliomas and curcumin may be an interesting drug to combat this characteristic.

CURCUMIN INDUCES OXIDATIVE STRESS AND APOPTOSIS IN GLIOMA CELL LINES

Curcumin has been shown to have cytotoxic effects in cancer cells via the production of reactive oxygen species (ROS). U87, U51, and U235 glioblastoma lines treated with 70 μM curcumin solution saw decreases in cellular viability to levels as low as 20%. At curcumin concentrations as low as 25 μM, immunofluorescence oxidative stress assays demonstrated induction of ROS at 1 and 6 hours, normalizing after 1 day (7). U373 glioblastoma cells treated with curcumin solution demonstrated preferential induction of apoptosis at concentrations of 10 μg/ml and similar levels of apoptosis and necrosis and curcumin concentrations of 20 μg/ml (41). This is contrary to the protective effect that curcumin exhibits against oxidative stress in normal tissue (26). This dual mode of action exerted by curcumin may be due to its ability to reduce oxidative stress and inflammatory response in normal cells while also having the ability to upregulate genes responsible for cell death in pathological conditions.

BARRIERS TO CURCUMIN AS A SYSTEMIC THERAPY

Despite curcumin’s apparent ability to reduce the malignant nature of glioblastoma in vitro via multiple mechanisms, it has failed to gain traction as a therapeutic agent. This, in part, may be due to curcumin’s poor systemic bioavailability. In vivo bioavailability studies indicate that the bioavailability of unaltered curcumin preparations (standard curcumin) is dismal. After all, a therapeutic agent is not useful if it cannot be effectively delivered to its target in sufficient quantities. There is evidence to suggest that curcumin crosses the blood-brain barrier and may offer some neuroprotective effects, especially in context of neurodegenerative diseases such as Alzheimer’s disease. In a murine model, curcumin was shown to decrease beta-amyloid plaque burden by 43% via blockage of beta amyloid self-assembly (42, 43). Similarly, curcumin’s anti-inflammatory properties, anti-oxidant properties, metal chelation properties, and ability to decrease lipid peroxidation and lipofuscin accumulation are thought to be neuroprotective (42). The extent or mechanism of transport of curcumin across the blood-brain barrier has not been well described in humans. Common explanations in favor of curcumin’s transport across the blood-brain barrier reference its lipophilic nature. However, critics are quick to mention that other large lipophilic molecules, such as cholesterol, cannot readily cross the blood-brain barrier. Specific transport mechanisms have not been described to date.

One of the main areas of focus for drug development of curcumin over the past years has been on preparations that increase its bioavailability. Factors that contribute to curcumin’s low systemic bioavailability include its large crystalline structure, low solubility in non-toxic solution, and extensive in vivo metabolism (15, 44). Low-crystallinity nanoparticles were formed by exposing curcumin preparations to solvents such as chloroform. Although these preparations increased bioavailability of curcumin, their toxic solvents limited use in humans. The advent of precipitation by pressure reduction of gas-expanded liquid (PPREGL) has enabled the production of spherical curcumin nanoparticles as small as 66 nm (44). PPREGL nanocurcumin preparations utilize carbon dioxide instead of other volatile solvents to dry and precipitate curcumin nanoparticles from a curcumin impregnated nanoporous starch aerogel (NSA). The bioavailability of curcumin NSA nanoparticles are 173 times greater than that of standard curcumin preparations (0.4% vs 69.1%) (44).

Other methods of curcumin preparation that increase bioavailability include liposomal curcumin and curcumin micelles. Curcumin micelles have 19-fold greater bioavailability compared to standard curcumin preparations (45). Unfortunately, micelle preparations have the drawback of a relatively large volume of stabilizers and excipients that may cause side effects such as hemolysis (46). Liposomal curcumin preparations are a promising established method of increasing curcumin bioavailability, with the ability to affix transport molecules to enhance transport across the blood-brain barrier. The p-Aminophenyl-α-D-mannopyranoside transport molecule enhances liposomal transport across the blood-brain barrier and selectively targets cortex, hippocampus, cerebellum, brainstem, and pontine nuclei (47).

CONCLUSION

There is a dire need for advancement in glioblastoma therapy. Standard-of-care chemotherapy with temozolomide and radiation has not changed for over a decade and the prognosis for glioblastoma is dismal. Curcumin has a positive safety profile and its interaction with cell cycle regulators and regulators of oxidative stress make it an attractive possible adjunct to current standard chemotherapeutic agents and radiation in the treatment of glioblastoma. In vitro studies have demonstrated that curcumin potentiates the effects of chemotherapy and radiation on glioblastoma cells, while decreasing the ability of glioblastoma to proliferate, migrate, and recover from oxidative stress. Curcumin’s main barrier to its potential use as a systemic agent is its poor bioavailability, limited by extensive modification by enterocytes and rapid metabolism. Recent progress has been made in enhancing curcumin’s bioavailability by production of non-toxic nanopreparations; however, they have yet to make their way into large studies or clinical trials. While there is limited in vivo data, in vitro data suggests that curcumin can be a safe and effective anti-glioblastoma agent. Additional high-quality studies regarding the safety and efficacy of high bioavailability curcumin preparations will be necessary to further elucidate the potential role of curcumin in glioblastoma treatment.

Conflict of Interest: The authors declare no potential conflicts of interest with respect to research, authorship and/or publication of this article.

Copyright and Permission Statement: The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced.

REFERENCES

1.

Wesseling P, Capper D. WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139–50. https://doi​.org/10.1111/nan.12432. [PubMed: 28815663]

2.

Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology. 2020;22 Supplement_1:iv1–iv96. https://doi​.org/10.1093/neuonc/noaa200. [PMC free article: PMC7596247] [PubMed: 33123732]

3.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. https://doi​.org/10.1056/NEJMoa043330. [PubMed: 15758009]

4.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):2306–16. https://doi​.org/10.1001/jama.2017.18718. [PMC free article: PMC5820703] [PubMed: 29260225]

5.

Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017;57(13):2889–95. https://doi​.org/10.1080/10408398​.2015.1077195. [PubMed: 26528921]

6.

Seyithanoğlu MH, Abdallah A, Kitiş S, Güler EM, Koçyiğit A, Dündar TT, et al. Investigation of cytotoxic, genotoxic, and apoptotic effects of curcumin on glioma cells. Cell Mol Biol (Noisy-le-grand). 2019;65(3):101–8. https://doi​.org/10.14715/cmb/2019​.65.3.15. [PubMed: 30942162]

7.

Gersey ZC, Rodriguez GA, Barbarite E, Sanchez A, Walters WM, Ohaeto KC, et al. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer. 2017;17(1):99. https://doi​.org/10.1186​/s12885-017-3058-2. [PMC free article: PMC5292151] [PubMed: 28160777]

8.

Wang X, Deng J, Yuan J, Tang X, Wang Y, Chen H, et al. Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells. Int J Oncol. 2017;51(2):467–77. https://doi​.org/10.3892/ijo.2017.4037. [PMC free article: PMC5505128] [PubMed: 28627598]

9.

Fratantonio D, Molonia MS, Bashllari R, Muscarà C, Ferlazzo G, Costa G, et al. Curcumin potentiates the antitumor activity of Paclitaxel in rat glioma C6 cells. Phytomedicine. 2019;55:23–30. https://doi​.org/10.1016/j​.phymed.2018.08.009. [PubMed: 30668434]

10.

Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The Essential Medicinal Chemistry of Curcumin. J Med Chem. 2017;60(5):1620–37. https://doi​.org/10.1021/acs​.jmedchem.6b00975. [PMC free article: PMC5346970] [PubMed: 28074653]

11.

Horosanskaia E, Yuan L, Seidel-Morgenstern A, Lorenz H. Purification of Curcumin from Ternary Extract-Similar Mixtures of Curcuminoids in a Single Crystallization Step. Crystals. 2020;10:206. https://doi​.org/10.3390/cryst10030206.

12.

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of Curcumin: Problems and Promises. Molecular Pharmaceutics. 2007;4(6):807–18. https://doi​.org/10.1021/mp700113r. [PubMed: 17999464]

13.

Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–6. https://doi​.org/10.1055/s-2006-957450. [PubMed: 9619120]

14.

Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007;595:453–70. https://doi​.org/10.1007​/978-0-387-46401-5_20. [PubMed: 17569224]

15.

Heger M, van Golen RF, Broekgaarden M, Michel MC. The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer. Pharmacological Reviews. 2014;66(1):222. https://doi​.org/10.1124/pr.110.004044. [PubMed: 24368738]

16.

Hewlings SJ, Kalman DS. Curcumin: A Review of Its’ Effects on Human Health. Foods. 2017;6(10):92. https://doi​.org/10.3390/foods6100092.

17.

Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003;9(1):161–8. https://doi​.org/10.1089​/107555303321223035. [PubMed: 12676044]

18.

Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: a unique target for tumor therapy. Cancer Cell International. 2016;16(1):49. https://doi​.org/10.1186​/s12935-016-0326-1. [PMC free article: PMC4917988] [PubMed: 27340370]

19.

Zhang S, Zhang C, Song Y, Zhang J, Xu J. Prognostic role of survivin in patients with glioma. Medicine (Baltimore). 2018;97(17):e0571. https://doi​.org/10.1097/MD​.0000000000010571. [PMC free article: PMC5944547] [PubMed: 29703049]

20.

Tong X, Yang P, Wang K, Liu Y, Liu X, Shan X, et al. Survivin is a prognostic indicator in glioblastoma and may be a target of microRNA-218. Oncol Lett. 2019;18(1):359–67. https://doi​.org/10.3892/ol.2019.10335. [PMC free article: PMC6539917] [PubMed: 31289507]

21.

Wu B, Yao X, Nie X, Xu R. Epigenetic reactivation of RANK in glioblastoma cells by curcumin: involvement of STAT3 inhibition. DNA Cell Biol. 2013;32(6):292–7. https://doi​.org/10.1089/dna.2013.2042. [PMC free article: PMC3665298] [PubMed: 23621850]

22.

Zuccarini M, Giuliani P, Ziberi S, Carluccio M, Iorio PD, Caciagli F, et al. The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor. Genes (Basel). 2018;9(2):105. https://doi​.org/10.3390/genes9020105. [PMC free article: PMC5852601] [PubMed: 29462960]

23.

Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810. https://doi​.org/10.1146/annurev​.cellbio.20.010403.113126. [PubMed: 15473860]

24.

Hesari A, Rezaei M, Rezaei M, Dashtiahangar M, Fathi M, Rad JG, et al. Effect of curcumin on glioblastoma cells. J Cell Physiol. 2019;234(7):10281–8. https://doi​.org/10.1002/jcp.27933. [PubMed: 30585634]

25.

Luo Q, Luo H, Fu H, Huang H, Huang H, Luo K, et al. Curcumin suppresses invasiveness and migration of human glioma cells in vitro by inhibiting HDGF/β-catenin complex. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2019;39(8):911–6. [PMC free article: PMC6765606] [PubMed: 31511210]

26.

Jagetia GC. Radioprotection and radiosensitization by curcumin. Adv Exp Med Biol. 2007;595:301–20. https://doi​.org/10.1007​/978-0-387-46401-5_13. [PubMed: 17569217]

27.

Godoy PRDV, Pour Khavari A, Rizzo M, Sakamoto-Hojo ET, Haghdoost S. Targeting NRF2, Regulator of Antioxidant System, to Sensitize Glioblastoma Neurosphere Cells to Radiation-Induced Oxidative Stress. Oxidative medicine and cellular longevity. 2020;2020:2534643. https://doi​.org/10.1155/2020/2534643. [PMC free article: PMC7315280] [PubMed: 32617133]

28.

Faktor J, Pjechová M, Hernychová L, Vojtěšek B. Protein Ubiquitination Research in Oncology. Klin Onkol. 2019;32 Supplementum 3:56–64. https://doi​.org/10.14735/amko20193S56. [PubMed: 31627707]

29.

Zou X, Levy-Cohen G, Blank M. Molecular functions of NEDD4 E3 ubiquitin ligases in cancer. Biochim Biophys Acta. 2015;1856(1):91–106. https://doi​.org/10.1016/j​.bbcan.2015.06.005. [PubMed: 26116757]

30.

Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4–1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128(1):129–39. https://doi​.org/10.1016/j​.cell.2006.11.039. [PMC free article: PMC1828909] [PubMed: 17218260]

31.

Deng T, Yan G, Song X, Xie L, Zhou Y, Li J, et al. Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression and DNA damage responses. Proc Natl Acad Sci U S A. 2018;115(18):4678–83. https://doi​.org/10.1073/pnas.1714938115. [PMC free article: PMC5939064] [PubMed: 29666278]

32.

Wu J, Su HK, Yu ZH, Xi SY, Guo CC, Hu ZY, et al. Skp2 modulates proliferation, senescence and tumorigenesis of glioma. Cancer Cell Int. 2020;20:71. https://doi​.org/10.1186​/s12935-020-1144-z. [PMC free article: PMC7059397] [PubMed: 32165861]

33.

Cai Z, Moten A, Peng D, Hsu CC, Pan BS, Manne R, et al. The Skp2 Pathway: A Critical Target for Cancer Therapy. Semin Cancer Biol. 2020. https://doi​.org/10.1016/j​.semcancer.2020.01.013. [PMC free article: PMC9201937] [PubMed: 32014608]

34.

Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A. 2001;98(9):5043–8. https://doi​.org/10.1073/pnas.081474898. [PMC free article: PMC33160] [PubMed: 11309491]

35.

Zhang W, Cao L, Sun Z, Xu J, Tang L, Chen W, et al. Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation. Cell Cycle. 2016;15(10):1344–51. https://doi​.org/10.1080/15384101​.2016.1160986. [PMC free article: PMC4889242] [PubMed: 27111245]

36.

Wang L, Ye X, Cai X, Su J, Ma R, Yin X, et al. Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells. Oncotarget. 2015;6(20):18027–37. https://doi​.org/10.18632/oncotarget.4090. [PMC free article: PMC4627233] [PubMed: 26046466]

37.

Smith SJ, Diksin M, Chhaya S, Sairam S, Estevez-Cebrero MA, Rahman R. The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour. Int J Mol Sci. 2017;18(11):2452. https://doi​.org/10.3390/ijms18112452. [PMC free article: PMC5713419] [PubMed: 29156557]

38.

Price SJ, Gillard JH. Imaging biomarkers of brain tumour margin and tumour invasion. Br J Radiol. 2011;84 Spec No 2(Spec Iss 2):S159–S67. https://doi​.org/10.1259/bjr/26838774. [PMC free article: PMC3473903] [PubMed: 22433826]

39.

Guo G, Sun Y, Hong R, Xiong J, Lu Y, Liu Y, et al. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Clin Transl Oncol. 2019. https://doi​.org/10.1007​/s12094-019-02251-3. [PubMed: 31865606]

40.

Tabouret E, Boudouresque F, Farina P, Barrié M, Bequet C, Sanson M, et al. MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. Neuro-oncology. 2015;17(8):1174–6. https://doi​.org/10.1093/neuonc/nov094. [PMC free article: PMC4490881] [PubMed: 26142442]

41.

Abdullah Thani NA, Sallis B, Nuttall R, Schubert FR, Ahsan M, Davies D, et al. Induction of apoptosis and reduction of MMP gene expression in the U373 cell line by polyphenolics in Aronia melanocarpa and by curcumin. Oncol Rep. 2012;28(4):1435–42. https://doi​.org/10.3892/or.2012.1941. [PubMed: 22842701]

42.

Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer’s disease: An overview. Ann Indian Acad Neurol. 2008;11(1):13–9. https://doi​.org/10.4103/0972-2327.40220. [PMC free article: PMC2781139] [PubMed: 19966973]

43.

Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892–901. https://doi​.org/10.1074/jbc.M404751200. [PubMed: 15590663]

44.

Ubeyitogullari A, Ciftci ON. A novel and green nanoparticle formation approach to forming low-crystallinity curcumin nanoparticles to improve curcumin’s bioaccessibility. Scientific Reports. 2019;9(1):19112. https://doi​.org/10.1038​/s41598-019-55619-4. [PMC free article: PMC6911079] [PubMed: 31836788]

45.

Zhang Q, Polyakov NE, Chistyachenko YS, Khvostov MV, Frolova TS, Tolstikova TG, et al. Preparation of curcumin self-micelle solid dispersion with enhanced bioavailability and cytotoxic activity by mechanochemistry. Drug Deliv. 2018;25(1):198–209. https://doi​.org/10.1080/10717544​.2017.1422298. [PMC free article: PMC6058497] [PubMed: 29302995]

46.

Li X, Yuan H, Zhang C, Chen W, Cheng W, Chen X, et al. Preparation and in-vitro/in-vivo evaluation of curcumin nanosuspension with solubility enhancement. J Pharm Pharmacol. 2016;68(8):980–8. https://doi​.org/10.1111/jphp.12575. [PubMed: 27283220]

47.

Wang Y, Ying X, Xu H, Yan H, Li X, Tang H. The functional curcumin liposomes induce apoptosis in C6 glioblastoma cells and C6 glioblastoma stem cells in vitro and in animals. Int J Nanomedicine. 2017;12:1369–84. https://doi​.org/10.2147/IJN.S124276. [PMC free article: PMC5325138] [PubMed: 28260885]

Doi: https://doi​.org/10.36255​/exonpublications​.gliomas.2021.chapter8